Biosight Ltd gathers $19m Series C

Biosight Ltd., an Israeli developer of treatments for hematological malignancies and disorders, has secured $19 million in Series C financing.

To view this content, you need to sign in.


You should only be asked to sign in once. Not the case? Click here


Register now to access this content and more for free.

Share this